Articles tagged "Antibodies"

2021 American Transplant Congress
Covid-19 Reinfection in a Kidney Transplant Patient
Z. Saeed Zafar, D. Malhotra
Nephrology, Yale School of Medicine, New Haven, CT
*Purpose: Several cases have demonstrated positive SARS-CoV-2 PCR testing in patients who were initially shown to have cleared the infection. These reinfections may represent new…
2021 American Transplant Congress
Short-term Therapy with Anti-icam-1 Monoclonal Antibody Induced Long-term Liver Allograft Survival in Non-human Primates
S. Hong¹, D. Han², S. Lee², J. Kim³, E. Hwang³, H. Kim⁴, J. Lee⁵, K. Hong¹, E. Han¹, J. Cho¹, J. Lee¹, Y. Choi¹, K. Lee¹, N. Yi¹, J. Yang¹, K. Suh¹
¹Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of, ²Biomedical Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of, ³Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁴Pathology, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁵Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: Tolerance induction remains challenging following liver transplantation and the long-term use of immunosuppressants, especially calcineurin inhibitors, leads to serious complications. We aimed to test…
2021 American Transplant Congress
The Relevance of Naturally Occurring Non-HLA Antibody to Antibody Mediated Rejection in Patients without Anti-HLA Antibodies After Kidney Transplantation
H. Ishida¹, T. Shimizu², K. Unagami³, H. Shirakawa¹, K. Tanabe¹
¹Tokyo Womens, Tokyo 162-8666, Japan, ²Urology, Tokyo Womens, Tokyo 162-8666, Japan, ³Nephrology, Tokyo Womens, Tokyo 162-8666, Japan
*Purpose: Very few papers describe the association between non-HLA antibodies and the incidence of antibody mediated rejection (AMR) in kidney recipients. We investigated the incidence…
2021 American Transplant Congress
A Comparison of Plasmapheresis Methods in the Treatment of Late Antibody Mediated Rejection
Y. Caliskan¹, H. Yazici², A. B. Dirim², E. Aksoy², S. Safak², N. Garayeva², S. Mirioglu², O. Yegit², O. A. Oto², Y. Ozluk³, S. Besisik⁴, A. Turkmen², K. Lentine¹
¹Saint Louis University, Saint Louis, MO, ²Division of Nephrology, Istanbul University, Istanbul, Turkey, ³Department of Pathology, Istanbul University, Istanbul, Turkey, ⁴Division of Hematology, Istanbul University, Istanbul, Turkey
*Purpose: Effective management to prevent allograft loss after late antibody mediated rejection (ABMR) in kidney transplant (KTx) recipients remains a vexing clinical challenge. While plasma…
2021 American Transplant Congress
Desensitization with Plasmapheresis and IV Immunoglobulin is Safe and Effective in Pra Positive Kidney Transplant Recipient Candidates in Covid-19 Pandemic Period
B. Sayin¹, A. Akdur², E. Karakaya², U. Musabak³, T. Colak¹, M. Haberal²
¹Department of Nephrology, Baskent University, Ankara, Turkey, ²Division of Transplantation, Department of General Surgery, Baskent University, Ankara, Turkey, ³Department of Immunology, Baskent University, Ankara, Turkey
*Purpose: High panel reactive antibody (PRA) levels may limit living-donor kidney transplantation (LDKT) according to increased risk of antibody mediated rejection. Desensitization may provide better…
2021 American Transplant Congress
Development of De Novo Antibody in Renal Transplant Recipients with BK Viremia Managed with Immunosuppression Reduction
R. Hod Dvorai¹, R. Lee², P. Muluhngwi², M. Raijmakers³, A. Shetty², A. Tambur², M. Ison²
¹SUNY Upstate Medical University, Syracuse, NY, ²Northwestern University, Chicago, IL, ³University of Santiago, Santiago, Chile
*Purpose: To evaluate development of de novo donor specific antibodies (dnDSA) in Renal Transplant Recipients (RTR) with immunosuppression (IS) modulation due to BK viremia (BKV)…
2021 American Transplant Congress
Evaluation of Rituximab-abbs in Renal Transplant: A Case Series
A. Dao¹, B. Jimenez², A. Reyad¹, J. Guiteau¹, M. Madhrira³, N. Umezurike¹, S. Patel¹, S. Allam³
¹Transplant, Medical City Fort Worth, Fort Worth, TX, ²College of Pharmacy, University of North Texas, Fort Worth, TX, ³Tarrant Nephrology Associates, Premier Physicians Group Health, Fort Worth, TX
*Purpose: Biosimilars are FDA-approved alternatives to cost-prohibitive biologics, with no clinically meaningful differences in safety, purity, and potency. Rituximab-abbs, a biosimilar to rituximab, has labeled…
2021 American Transplant Congress
Systematic Screening of Kidney Transplant Patients Points Towards Deficits in Neutralizing Antibody Capacity Against Sars-cov-2
V. Wijtvliet¹, K. K. Ariën², J. Mariën², B. Peeters³, R. Hellemans⁴, A. Massart⁴, S. Van Hees¹, P. Moons⁵, H. Theeten⁶, P. Van Damme⁶, H. Goossens⁷, B. Y. De Winter¹, K. J. Ledeganck¹, D. Abramowicz⁴
¹Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium, ²Department of Biomedical Sciences, Institute of Tropical Medicine and University of Antwerp, Antwerp, Belgium, ³Department of Laboratory Medicine, Antwerp University Hospital, Antwerp, Belgium, ⁴Department of Nephrology and Hypertension, Antwerp University Hospital, Antwerp, Belgium, ⁵Biobank, Antwerp University Hospital, Antwerp, Belgium, ⁶Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium, ⁷Department of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium
*Purpose: The majority of kidney transplant recipients (KTR) is able to develop SARS-CoV-2 antibodies (Abs). Little is known about the virus neutralizing capacity of these…
2021 American Transplant Congress
Successful Prophylaxis of Antibody-Mediated Rejection by Downregulation of C5 Expression via RNA Interference in a Rat Kidney Transplant Model
H. Ishigooka¹, S. Motoi², T. Yamakawa¹, C. Matsui², Y. Suzuki³, R. Ishii¹, K. Saiga¹, D. Tokita¹, T. Imai², K. Tanabe¹
¹Urology, Tokyo Women's Medical University, Tokyo, Japan, ²KAN Research Institute, Inc., Kobe, Japan, ³Tsukuba Research Laboratories, Eisai, Co., Ltd., Ibaraki, Japan
*Purpose: Antibody-mediated rejection (AMR) is a major contributor towards poor prognosis in kidney transplantation. Circulating donor-specific antibodies (DSAs) cause AMR with complement activation. This study…
2021 American Transplant Congress
A2 to B Deceased Donor Renal Transplantation Outcome Analysis: Single Center Experience
S. Bindroo, M. Doshi
Nephrology, University of Michigan, Ann Arbor, MI
*Purpose: Initial experience under kidney allocation system (KAS) implemented in December 2014 showed equivalent outcomes for A2 to B kidney transplantation compared with ABO compatible…

« Previous Page
1
…
8
9
10
11
12
…
57
Next Page »